The DOI matches its Crossref record.
Cytochrome P450 and Liver Diseases
Abstract
Cytochrome P-450 (CYPs) are involved in the metabolism of drugs, chemicals and endogenous substrates. The hepatic CYPs are also involved in the pathogenesis of several liver diseases. CYP-mediated activation of drugs to toxic metabolites induces hepatotoxicity. Well-known examples include acetaminophen and halothane. In some instances, covalent binding of the toxic metabolite to CYP leads to the formation of anti-CYP antibodies and immune-mediated hepatotoxicity (hydralazine, tienilic acid). Anti-CYP2D6 antibodies are also present in the serum of patients with type II autoimmune hepatitis, but the mechanism leading to their presence and their pathogenic significance remains unclear. Several studies support a role for CYP2E1 in the pathogenesis of alcoholic liver disease and non-alcoholic steatohepatitis. In these conditions, enhanced CYP2E1 activity is associated with lipid peroxidation and the production of reactive oxygen species with secondary damage to cellular membranes and mitochondria. Because of its ability to activate carcinogens, a role for CYP2E1 as a cofactor for hepatocellular carcinoma has also been postulated. On the other hand, drug metabolism is impaired in patients with liver disease, particularly that mediated by CYPs. The content and activity of CYP1A, 2C19 and 3A appear to be particularly vulnerable to the effect of liver disease while CYP2D6, 2C9 and 2E1 are less affected. The pattern of CYPs isoenzymes alterations also differs according to the etiology of liver disease. A strong relationship between the activity of CYPs and the severity of cirrhosis has been demonstrated, but the usefulness of measuring CYP activity to assess hepatic functional reserve remains uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652
Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027466 · Cited by 352
The role of hyperosmotic stress in inflammation and disease
Brocker, C., Thompson, D. C., & Vasiliou, V. (2012) · bmc · doi:10.1515/bmc-2012-0001 · Cited by 304
Pain Management in the Cirrhotic Patient: The Clinical Challenge
Chandok, N., & Watt, K. D. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0534 · Cited by 291
Tarantino, G., Conca, P., Basile, V., Gentile, A., Capone, D., Polichetti, G., & Leo, E. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00072.x · Cited by 145
Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
Chale-Dzul, J., Pérez-Cabeza de Vaca, R., Quintal-Novelo, C., Olivera-Castillo, L., & Moo-Puc, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.183 · Cited by 47
Sun, Y., Yin, S., Cui, J., Wang, Z., Han, Y., Ma, D., Wang, S., Wu, J., Cao, Y., Jiang, C., et al. (2024) · Nano Research · doi:10.1007/s12274-023-5940-3 · Cited by 13
Metadata
- Authors
- Villeneuve, J.-P., & Pichette, V.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-06-01
- Volume
- 5
- Issue
- 3
- Pages
- 273-282
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2012225071
- Cited by
- 215
- References
- 0
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.